Literature DB >> 20030680

Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation.

Masakatsu Yanagimachi1, Takuya Naruto, Reo Tanoshima, Hiromi Kato, Tomoko Yokosuka, Ryosuke Kajiwara, Hisaki Fujii, Fumiko Tanaka, Hiroaki Goto, Tatsuhiko Yagihashi, Kenjiro Kosaki, Shumpei Yokota.   

Abstract

BACKGROUND: One severe side effect of calcineurin inhibitors (CNIs: such as cyclosporine [CsA] and tacrolimus [FK506]) is neurotoxicity. CNIs are substrates for CYP3A5 and P-glycoprotein (P-gp), encoded by ABCB1 gene. In the present study, we hypothesized that genetic variability in CYP3A5 and ABCB1 genes may be associated with CNI-related neurotoxicity.
METHODS: The effects of the polymorphisms, such as CYP3A5 A6986G, ABCB1 C1236T, G2677T/A, and C3435T, associated with CNI-related neurotoxicity were evaluated in 63 patients with hematopoietic stem cell transplantation.
RESULTS: Of the 63 cases, 15 cases developed CNI-related neurotoxicity. In the CsA patient group (n = 30), age (p = 0.008), hypertension (p = 0.017), renal dysfunction (p < 0.001), ABCB1 C1236T (p < 0.001), and G2677T/A (p = 0.014) were associated with neurotoxicities. The CC genotype at ABCB1 C1236T was associated with it, but not significantly so (p = 0.07), adjusted for age, hypertension, and renal dysfunction. In the FK506 patient group (n = 33), CYP3A5 A6986G (p < 0.001), and ABCB1 C1236T (p = 0.002) were associated with neurotoxicity. At least one A allele at CYP3A5 A6986G (expressor genotype) was strongly associated with it according to logistic regression analysis (p = 0.01; OR, 8.5; 95% CI, 1.4-51.4).
CONCLUSION: The polymorphisms in CYP3A5 and ABCB1 genes were associated with CNI-related neurotoxicity. This outcome is probably because of CYP3A5 or P-gp functions or metabolites of CNIs.
© 2009 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20030680     DOI: 10.1111/j.1399-0012.2009.01181.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  16 in total

Review 1.  PharmGKB summary: cyclosporine and tacrolimus pathways.

Authors:  Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

Review 2.  Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.

Authors:  Alessio Provenzani; Andrew Santeusanio; Erin Mathis; Monica Notarbartolo; Manuela Labbozzetta; Paola Poma; Ambra Provenzani; Carlo Polidori; Giovanni Vizzini; Piera Polidori; Natale D'Alessandro
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

3.  The impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients.

Authors:  Olivia Campagne; Donald E Mager; Daniel Brazeau; Rocco C Venuto; Kathleen M Tornatore
Journal:  Br J Clin Pharmacol       Date:  2019-01-04       Impact factor: 4.335

4.  Neurological Complications after Renal Transplantation: A Retrospective Clinical Study.

Authors:  Nilgün Cengiz; Zelal Adibelli; Yarkın Kamil Yakupoğlu; Hande Türker
Journal:  Noro Psikiyatr Ars       Date:  2015-12-01       Impact factor: 1.339

5.  Mind the Gaps: Ontogeny of Human Brain P-gp and Its Impact on Drug Toxicity.

Authors:  Jean-Marie Nicolas; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2019-05-28       Impact factor: 4.009

Review 6.  Central modulation of cyclosporine-induced hypertension.

Authors:  Hanan M El-Gowelli; Mahmoud M El-Mas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-11-29       Impact factor: 3.000

7.  Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease.

Authors:  Isabelle Laverdière; Chantal Guillemette; Ryad Tamouza; Pascale Loiseau; Regis Peffault de Latour; Marie Robin; Félix Couture; Alain Filion; Marc Lalancette; Alan Tourancheau; Dominique Charron; Gérard Socié; Éric Lévesque
Journal:  Haematologica       Date:  2014-11-25       Impact factor: 9.941

8.  Risk Factors for Subtherapeutic Tacrolimus Levels after Conversion from Continuous Intravenous Infusion to Oral in Children after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Michelle Kolb; Katharine Offer; Zhezhen Jin; Justine Kahn; Monica Bhatia; Andrew L Kung; James H Garvin; Diane George; Prakash Satwani
Journal:  Biol Blood Marrow Transplant       Date:  2016-02-13       Impact factor: 5.742

Review 9.  The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.

Authors:  Dennis A Hesselink; Rachida Bouamar; Laure Elens; Ron H N van Schaik; Teun van Gelder
Journal:  Clin Pharmacokinet       Date:  2014-02       Impact factor: 6.447

Review 10.  Epileptic Seizures After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Zhuo Wang; Munan Zhao; Sujun Gao
Journal:  Front Neurol       Date:  2021-07-16       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.